Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Turner NC; Huang  Bartlett C; Cristofanilli M

doi:10.1056/nejmc1510345

Abstract

No abstract provided.

Full text links

Read article at publisher's site: https://doi.org/10.1056/nejmc1510345

References

Articles referenced by this article (4)

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group, Turner N, Andre F, Cristofanilli M, Gluck S, Harbeck N, Iwata H, Loi S, Loibl S, Verma S, Vermorken JB, Seidman AD, Emerson SS, Antill Y, Harvey S, Harris M, Ganju V, Oakman C, Redfern A, Slancar M, Khasraw M, Cronk M, Lombard J, Dirix L, Canon J-, Confente C, Wynendaele W, Neven P, Vuylsteke P, Baurain J-, Duck L, Forget F, Awada A, Dopchie C, Verma S, Bin J, Li I, Verma S, Elser C, Miller W, Findlay B, Martin LA, Ellard S, Freedman O, Loibl S, Forstmeyer D, Harbeck N, Murphy C, Soto Parra H, Zamagni C, Colleoni M, Barone C, De Laurentis M, Gianni L, Roila F, Amadori D, Inoue K, Iwata H, Mukai H, Masuda N, Rai Y, Hara F, Ishida M, Nakamura R, Kim S-, Ro J, Im S-, Im Y-, Kim JH, Kroep J, Portielje J, de Jongh F, van Alphen R, Erdkamp F, de Boer M, Cardoso F, Bordalo e Sa J, Toganel C, Ganea DE, Crihana C, Turcu A, Vladimirov V, Lipatov O, Komov D, Fadeeva N, Krasnozhon D, Chang T-, Gokmen E, Shevnia S, Berzoy O, Shparyk Y, Hontsa A, Vinnyk Y, Archer C, Turner N, Coleman R, Barrett-Lee P, Henderson C, Kalmadi S, Wilkinson M, Goldberg J, Tiber C, Beeker T, Kabos P, O'Rourke T, Link J, Citron M, Margileth D, DeMichele A, Helsten T, Stearns V, Vaklavas C, Sleckman B, Dillon P, Hetzel D, Niu J, Dichmann R, Lawler W, DiCarlo B, Calfa C, Chan D, Allison MA, Jones C, Waisman J, Krill-Jackson E, Mahtani R, Potter D, Burness M, Caballero Monge AG, Huggines-Puhalla S, Slamon D, Beck A, Toppmeyer D, Rao R, Patel R, Jaslow R, Weisberg T, Chalasani P, Rakkar AN, Lashkari A, Adoo C, McIntyre K, Houck W 3rd, Vukelja S, Wilks S, Restrepo A, Rugo H, Danso M, Robert N, Hermann R, Lindquist D, Ellis E, Moroose R
N Engl J Med, (3):209-219 2015
MED: 26030518
Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly?
Soria JC
Eur J Cancer, (10):1443-1445 2011
MED: 21555215
Targeted therapies: redefining the primary objective of phase I oncology trials.
Ratain MJ
Nat Rev Clin Oncol, (9):503-504 2014
MED: 25091610
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ
Lancet Oncol, (1):25-35 2014
MED: 25524798

Citations & impact

Impact metrics

59

Citations

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/4660622

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/4660622

Article citations

First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.
Kimmick G, Pilehvari A, You W, Bonilla G, Anderson R
Breast Cancer Res Treat, 208(2):263-273, 26 Jun 2024
Cited by: 0 articles | PMID: 38922546 | PMCID: PMC11455668
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.
McGrath MK, Abolhassani A, Guy L, Elshazly AM, Barrett JT, Mivechi NF, Gewirtz DA, Schoenlein PV
Front Endocrinol (Lausanne), 15:1298423, 18 Mar 2024
Cited by: 1 article | PMID: 38567308 | PMCID: PMC10986181
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Aromatase inhibitors: the journey from the state of the art to clinical open questions.
Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C, De Placido S
Front Oncol, 13:1249160, 22 Dec 2023
Cited by: 1 article | PMID: 38188305 | PMCID: PMC10770835
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer.
Gomes I, Abreu C, Costa L, Casimiro S
Cancers (Basel), 15(19):4835, 02 Oct 2023
Cited by: 3 articles | PMID: 37835528 | PMCID: PMC10571967
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K
Cancer Res, 83(19):3264-3283, 01 Oct 2023
Cited by: 5 articles | PMID: 37384539

Go to all (59) article citations

Search life-sciences literature (45,100,050 articles, preprints and more)

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

ORCIDs linked to this article

Abstract

Full text links

References

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly?

Targeted therapies: redefining the primary objective of phase I oncology trials.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.

Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.

Aromatase inhibitors: the journey from the state of the art to clinical open questions.

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer.

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.

Similar Articles

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Palbociclib--Taking Breast-Cancer Cells Out of Gear.

Palbociclib Extends Survival in Advanced Breast Cancer.

Palbociclib: first global approval.

Partnerships & funding

Similar Articles

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
N Engl J Med, 373(17):1672-1673, 01 Oct 2015

Palbociclib--Taking Breast-Cancer Cells Out of Gear.
N Engl J Med, 373(3):273-274, 01 Jul 2015

Palbociclib Extends Survival in Advanced Breast Cancer.
Cancer Discov, 5(7):OF5, 02 Jun 2015

Palbociclib: first global approval.
Drugs, 75(5):543-551, 01 Apr 2015

Search life-sciences literature (45,100,050 articles, preprints and more)

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Author information

ORCIDs linked to this article

Abstract

Full text links

References

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Similar Articles

Partnerships & funding